Corvus Pharmaceuticals 将来の成長

Future 基準チェック /06

Corvus Pharmaceuticalsは、15.1%と64.2%でそれぞれ年率15.1%で利益と収益が成長すると予測される一方、EPSはgrowで11.5%年率。

主要情報

15.1%

収益成長率

11.53%

EPS成長率

Biotechs 収益成長	23.0%
収益成長率	64.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 Mar 2026

今後の成長に関する最新情報

Recent updates

Late Stage ITK Inhibitor Franchise Will Transform Immunology Pipeline Over The Long Term

Mar 19Catalysts About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing soquelitinib, a selective ITK inhibitor, for cancers and immune inflammatory diseases. What are the underlying business or industry changes driving this perspective?

Targeted Immunology Pipeline Will Position This Biotech For Multiple Long Term Catalysts

Mar 05Catalysts About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing soquelitinib, an oral ITK inhibitor, for immune and inflammatory diseases and T cell lymphomas. What are the underlying business or industry changes driving this perspective?

Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know

Jan 21

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Nov 01

Is Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Trading At A 49% Discount?

Aug 19

Corvus Pharmaceuticals (NASDAQ:CRVS) Is In A Good Position To Deliver On Growth Plans

Jul 15

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Mar 28

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16

業績と収益の成長予測

NasdaqGM:CRVS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	58	-57	-53	-87	5
12/31/2027	8	-74	-67	-81	5
12/31/2026	N/A	-65	-62	-66	5
12/31/2025	N/A	-15	-33	-33	N/A
9/30/2025	N/A	-15	-32	-32	N/A
6/30/2025	N/A	-45	-29	-29	N/A
3/31/2025	N/A	-41	-29	-29	N/A
12/31/2024	N/A	-62	-25	-25	N/A
9/30/2024	N/A	-57	-22	-22	N/A
6/30/2024	N/A	-23	-21	-21	N/A
3/31/2024	N/A	-25	-21	-21	N/A
12/31/2023	N/A	-27	-24	-24	N/A
9/30/2023	N/A	-30	-26	-26	N/A
6/30/2023	N/A	-39	-28	-28	N/A
3/31/2023	N/A	-41	-29	-29	N/A
12/31/2022	N/A	-41	-27	-27	N/A
9/30/2022	N/A	-41	-27	-26	N/A
6/30/2022	N/A	-37	-28	-28	N/A
3/31/2022	N/A	-40	-34	-34	N/A
12/31/2021	N/A	-43	-37	-37	N/A
9/30/2021	N/A	-7	-38	-38	N/A
6/30/2021	N/A	-6	-37	-37	N/A
3/31/2021	N/A	-5	-34	-34	N/A
12/31/2020	N/A	-6	-35	-35	N/A
9/30/2020	N/A	-44	-35	-35	N/A
6/30/2020	N/A	-46	-38	-38	N/A
3/31/2020	N/A	-48	-38	-38	N/A
12/31/2019	N/A	-47	-37	-37	N/A
9/30/2019	N/A	-46	N/A	-37	N/A
6/30/2019	N/A	-46	N/A	-37	N/A
3/31/2019	N/A	-44	N/A	-39	N/A
12/31/2018	N/A	-47	N/A	-41	N/A
9/30/2018	N/A	-48	N/A	-44	N/A
6/30/2018	N/A	-51	N/A	-44	N/A
3/31/2018	N/A	-54	N/A	-45	N/A
12/31/2017	N/A	-56	N/A	-46	N/A
9/30/2017	N/A	-55	N/A	-45	N/A
6/30/2017	N/A	-52	N/A	-41	N/A
3/31/2017	N/A	-46	N/A	-35	N/A
12/31/2016	N/A	-36	N/A	-28	N/A
9/30/2016	N/A	-31	N/A	-22	N/A
6/30/2016	N/A	-24	N/A	-19	N/A
3/31/2016	N/A	-36	N/A	-15	N/A
12/31/2015	N/A	-31	N/A	-11	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CRVS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CRVS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CRVS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CRVS来年は収益がないと予測されています。

高い収益成長: CRVS来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CRVSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/04/01 20:06
終値	2026/04/01 00:00
収益	2025/12/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Corvus Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。12

アナリスト	機関
Etzer Darout	Barclays
Dane Leone	BTIG
Li Wang Watsek	Cantor Fitzgerald & Co.

Corvus Pharmaceuticals 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 9.1% to US$7.50

Price target decreased to US$2.50

Price target increased to US$6.38

Price target increased to US$6.30

Price target increased to US$7.38

Price target decreased to US$6.50

Recent updates

Late Stage ITK Inhibitor Franchise Will Transform Immunology Pipeline Over The Long Term

Corvus Pharmaceuticals, Inc. to Report Q4, 2025 Results on Mar 12, 2026

Targeted Immunology Pipeline Will Position This Biotech For Multiple Long Term Catalysts

Corvus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $174.999996 million.

Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know

Corvus Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $100 million.

Corvus Pharmaceuticals, Inc. Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc. to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 04, 2025

Corvus Pharmaceuticals, Inc. Announces Presentation of Interim Data from the Phase 1B/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer At the European Society for Medical Oncology (ESMO) Congress 2025

Corvus Pharmaceuticals, Inc. Appoints David Moore to the Board, Compensation Committee of the Board and the Nominating Committee, Effective October 2, 2025

Is Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Trading At A 49% Discount?

Corvus Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Corvus Pharmaceuticals (NASDAQ:CRVS) Is In A Good Position To Deliver On Growth Plans

Corvus Pharmaceuticals, Inc. Announces Partner Angel Pharmaceuticals Receives Ind Approval for A Phase 1B/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

Corvus Pharmaceuticals, Inc. Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc. Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2025

Corvus Pharmaceuticals, Inc. Appoints Richard Van Den Broek as Class II Director and Member of Audit and Nominating Committee, Effective April 8, 2025

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Corvus Pharmaceuticals, Inc. Announces Presentation of Additional Data from the Phase 1/1B Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Corvus Pharmaceuticals, Inc. to Report Q4, 2024 Results on Mar 25, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome

Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance

Corvus Pharmaceuticals, Inc. Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Corvus Pharmaceuticals, Inc. Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Corvus Pharmaceuticals: The Market Likes The Story

Corvus Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy

Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Corvus Pharmaceuticals, Inc Grants FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Corvus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Corvus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30.567011 million.

Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $30.567011 million.

Corvus Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Price target increased by 9.1% to US$7.50

Corvus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 19, 2024

New minor risk - Market cap size

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

New major risk - Revenue and earnings growth

Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer

Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors

Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

New major risk - Financial position

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Corvus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Corvus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Corvus Pharmaceuticals, Inc. Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

New minor risk - Market cap size

Corvus Pharmaceuticals, Inc. Presents New Cpi-818 Interim Data At the International Conference on Malignant Lymphoma

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Price target decreased to US$2.50

Insufficient new directors

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Price target increased to US$6.38